Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1)
Department of Medicine, Division of Community Internal Medicine
Clinical Epidemiology | Epidemiology | Health Services Administration | Health Services Research | Infectious Disease | Virus Diseases
Remdesivir, a broad-spectrum antiviral agent administered intravenously, was developed and studied as a potential treatment for Ebola virus disease and Marburg virus infection. In vitro and in vivo preclinical studies found antiviral activity for remdesivir against corona-like viruses, including Middle East respiratory syndrome coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV-1), the circulating human coronaviruses HCoV-OC42 and HCoV-229E, and SARS-CoV-2. Currently, the effectiveness of remdesivir is being tested as a treatment for patients infected with SARS-CoV-2 (COVID-19) and has been authorized for emergency use for treating COVID-19, by the U.S. Food and Drug Administration in the United States, and in other countries.
The American College of Physicians (ACP) Scientific Medical Policy Committee (SMPC) based these rapid and living practice points on a systematic evidence review conducted by the U.S. Department of Veterans Affairs (VA) Evidence Synthesis Program in Minneapolis, Minnesota. This version of the practice points, based on a search completed on 3 June 2020 and updated through 31 August 2020, was approved by the ACP's Executive Committee of Board of Regents on behalf of the Board of Regents on 14 August 2020 and submitted to Annals of Internal Medicine on 13 August 2020. Because many studies are planned or under way, literature surveillance is ongoing, with updates currently planned for every 2 months through December 2021. The target audience for these practice points includes clinicians and the public. The target patient population includes all nonpregnant patients with COVID-19.
remdesivir, COVID-19, clinical guidelines, practice points, Pulmonary diseases, Upper respiratory tract infections, Lungs, Patients, SARS coronavirus, Health care providers, Infectious diseases
DOI of Published Version
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Forciea MA, Miller MC, Humphrey LL. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1). Ann Intern Med. 2020 Oct 5. doi: 10.7326/M20-5831. Epub ahead of print. PMID: 33017175. Link to article on publisher's site
Annals of internal medicine
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Forciea MA, Miller MC, Humphrey LL. (2020). Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1). COVID-19 Publications by UMMS Authors. https://doi.org/10.7326/M20-5831. Retrieved from https://escholarship.umassmed.edu/covid19/125